Raj K. Puri, Chief Regulatory Officer of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), filed a Form 4 on September 10, 2026, disclosing transactions in common stock and restricted stock units dated September 8, 2026.
Key Highlights
- RSU vesting: 9,766 shares of common stock were acquired at $0 as a result of restricted stock units vesting on September 8, 2026.
- Tax withholding: 4,478 shares were disposed of at $8.70 per share, withheld by the issuer to satisfy mandatory tax withholding requirements upon RSU vesting.
- Shares retained: Following the transactions, Puri directly held 256,364 shares of common stock.
- Remaining RSUs: 58,599 RSUs remain outstanding from the grant dated March 5, 2025, vesting in equal quarterly installments.
- No open-market sale: According to the filing, the share disposal "is not an open market sale of securities."
RSU Vesting Transaction Details for Iovance Biotherapeutics Chief Regulatory Officer
According to the Form 4 filed with the SEC, Raj K. Puri, serving as Chief Regulatory Officer of Iovance Biotherapeutics, Inc., reported two transactions in the company's common stock on September 8, 2026. The first transaction, coded "M," reflects the acquisition of 9,766 shares at a price of $0, representing shares underlying restricted stock units that vested on the transaction date. Each RSU represents, per the filing, "a contingent right to receive one share of the Issuer's common stock."
The second transaction, coded "F," reflects the disposal of 4,478 shares at $8.70 per share. The filing states these are "shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs." The filing explicitly notes this disposal "is not an open market sale of securities." After these two transactions, Puri directly held 256,364 shares of common stock, which the filing describes as "the common stock remaining after deducting the common stock withheld for taxes."
In Table II, the filing records the settlement of 9,766 derivative securities (RSUs) through the "M" transaction code, reducing Puri's RSU position. The filing discloses that 58,599 RSUs remain from the grant issued on March 5, 2025, and notes that the remaining RSUs will vest in equal quarterly installments. The filing specifies this aggregate RSU figure does not include any other RSUs held by Puri.
What Was Disclosed
The filing disclosed the vesting of 9,766 RSUs, the withholding of 4,478 shares for tax purposes at $8.70 per share, a resulting direct common stock holding of 256,364 shares, and 58,599 RSUs remaining from a March 5, 2025 grant.




Please wait processing your request...